Your browser doesn't support javascript.
loading
The impact of pre-primary percutaneous coronary intervention β blocker use on the no-reflow phenomenon in patients with acute myocardial infarction / 中华心血管病杂志
Chinese Journal of Cardiology ; (12): 822-826, 2014.
Article Dans Chinois | WPRIM | ID: wpr-303820
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the impact of pre-primary percutaneous coronary intervention (PCI) β blocker use on the development of no-reflow in ST-segment elevation myocardial infarction (STEMI) patients post PCI.</p><p><b>METHODS</b>We retrospectively evaluated 1 615 outpatients with STEMI who underwent primary primary PCI with in 12 hours from symptom onset admitted to Beijing Anzhen Hospital and Chinese people's liberation army general hospital from January 2007 to June 2011. The study population was divided into the following 2 groups β blocker group (pretreatment with β blockers ≥ one month before admission, n = 257) and non-β blockers group (pretreatment with β blockers < one month before admission or had no β blocker, n = 1 358). No-reflow was defined as TIMI grade < 3 in last imaging of coronary artery after stenting. Multivariable logistic regression analyses were used to identify independent predictors for the no-reflow after primary PCI.</p><p><b>RESULTS</b>Incidence of the no-reflow was significantly lower in the β blocker group than in non-β blockers group (13.6% (35/257) vs. 21.2% (289/1 358), P = 0.017). Multivariable logistic regression analysis revealed that pre-PCI β blocker use was a protective predictor of the no-reflow (OR = 0.594, 95%CI0.394-0.893, P = 0.012), while age ≥ 55 years old (OR = 2.734, 95%CI1.959-3.817, P < 0.001), high neutrophil count (OR = 1.257, 95%CI 1.169-1.351, P < 0.001), admission plasma glucose (OR = 1.060, 95%CI1.018-1.103, P = 0.004), Killip classes IV (OR = 3.383, 95%CI1.924-5.948, P < 0.001) and reperfusion time ≥ 4 h(OR = 1.503, 95%CI1.124-2.009, P = 0.006) were risk factors for the development of no-reflow post PCI.</p><p><b>CONCLUSION</b>Previous long term β blockers use before STEMI is associated with lower incidence of no-reflow in patients with STEMI treated with primary PCI.</p>
Sujets)
Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Thérapeutique / Angioplastie coronaire par ballonnet / Endoprothèses / Études rétrospectives / Facteurs de risque / Antagonistes bêta-adrénergiques / Utilisations thérapeutiques / Phénomène de non reperfusion / Infarctus du myocarde antérieur / Intervention coronarienne percutanée Type d'étude: Etude d'étiologie / Étude observationnelle / Étude pronostique / Facteurs de risque Limites du sujet: Adulte très âgé / Femelle / Humains / Mâle langue: Chinois Texte intégral: Chinese Journal of Cardiology Année: 2014 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Thérapeutique / Angioplastie coronaire par ballonnet / Endoprothèses / Études rétrospectives / Facteurs de risque / Antagonistes bêta-adrénergiques / Utilisations thérapeutiques / Phénomène de non reperfusion / Infarctus du myocarde antérieur / Intervention coronarienne percutanée Type d'étude: Etude d'étiologie / Étude observationnelle / Étude pronostique / Facteurs de risque Limites du sujet: Adulte très âgé / Femelle / Humains / Mâle langue: Chinois Texte intégral: Chinese Journal of Cardiology Année: 2014 Type: Article